Stem cell infrastructure report

 

 

This review was undertaken by an MRC expert group in late 2007 to consider the progress of human stem cell research towards applications and the UK's requirements for research infrastructure to support this goal.

 

 

 

Executive summary

1 Purpose of review

 

2 The UK and stem cell research

 

3 MRC stem cell research portfolio 
  3.1 Research grant funding 
  3.2 Capacity building 
  3.3 Infrastructural investment 
  3.4 Strategic initiatives

 

4 State of the science 
  4.1 Sources of stem cells 
   i) Adult stem cells 
   ii) Fetal stem cells 
   iii) Embryonic stem cells (hESCs) 
   iv) Endogenous stem cells 
   v) Somatic cell nuclear transfer (SCNT) 
   vi) Induced pluripotent stem cells (iPS cells) 
  4.2 Supply of stem cells 
   i) Governance of hESC lines 
   ii) UK Stem Cell Bank 
   iii) Other sources (international) 
  4.3 Therapeutic development 
   i) Background 
   ii) Cardiac disease 
   iii) Diabetes type 1 
   iv) Neurodegenerative disease 
  4.4 Requirements for basic, translational and clinical research 
   i) Drug development 
   ii) Disease modelling

 

5 Regulation 
  5.1 EU Cells and Tissue Directive (2004/23/EC) 
  5.2 UK Regulation

 

6 Recommendations of the Expert Group
Annex: Methods used to conduct review
References: